23 Jul GENE-THERAPEUTIC DNA VECTOR BASED ON THE GENE-THERAPEUTIC DNA VECTOR VTvaf17, CARRYING THE TARGET GENE SELECTED FROM THE GROUP OF SKI, TGFB3, TIMP2, FMOD GENES TO INCREASE THE LEVEL OF EXPRESSION OF THESE TARGET GENES, A METHOD FOR PREPARING AND USING IT, ESCHERICHIA COLI SCS110-AF/VTvaf17-SKI STRAIN OR ESCHERICHIA COLI SCS110-AF/VTvaf17-TGFB3 OR ESCHERICHIA COLI SCS110-AF/VTvaf17-TIMP2 OR ESCHERICHIA COLI SCS110-AF/VTvaf17-FMOD, CARRYING A GENE-THERAPEUTIC DNA VECTOR, A METHOD FOR PRODUCTION THEREOF, A METHOD FOR INDUSTRIAL PRODUCTION OF A GENE-THERAPEUTIC DNA VECTOR
Abstract
FIELD: biochemistry.SUBSTANCE: invention relates to genetic engineering. Described is a gene-therapeutic DNA vector based on the gene-therapeutic DNA vector VTvaf17 for treating diseases characterized by developing tissue fibrosis, scar formation, connective tissue damage and accelerated wound healing, re-epithelialization, to increase formation of granulation tissue and inhibition of scar tissue formation, by increasing expression level of target SKI gene in human body and animals, wherein the gene-therapeutic DNA vector contains a coding portion of the target SKI gene cloned into the VTvaf17 genotyping DNA vector to obtain a VTvaf17-SKI gene-therapeutic DNA vector, with the nucleotide sequence SEQ ID No. 1. What is also described is a gene-therapeutic DNA vector based on the VTvaf17 gene-therapeutic DNA vector for treating diseases characterized by developing tissue fibrosis, scar formation, connective tissue damage and accelerated wound healing, re-epithelialization, to increase formation of granulation tissue and inhibition of scar tissue formation, by increasing expression level of target gene TGFB3, wherein the gene-therapeutic DNA vector comprises a coding portion of the target TGFB3 gene cloned into the VTvaf17 gene-therapeutic DNA vector to obtain a VTvaf17-TGFB3 gene-therapeutic DNA vector with the nucleotide sequence SEQ ID No. 2. What is also described is a gene-therapeutic DNA vector based on the gene-therapeutic DNA vector VTvaf17 for treating diseases characterized by developing tissue fibrosis, scar formation, connective tissue damage and accelerated wound repair, re-epithelialization, to increase the formation of granulation tissue and to inhibit the formation of scar tissue, by increasing the expression level of the target TIMP2 gene, wherein the gene-therapeutic DNA vector contains a coding portion of the target TIMP2 gene cloned into the VTvaf17 gene-genetic DNA vector, to obtain a VTvaf17-TIMP2 gene-therapeutic DNA vector, with the nucleotide sequence SEQ ID No. 3. What is also described is a gene-therapeutic DNA vector based on the VTvaf17 gene-therapeutic DNA vector for treating diseases characterized by developing tissue fibrosis, scar formation, connective tissue damage and accelerated wound repair, re-epithelialization, to increase formation of granulation tissue and inhibition of scar tissue formation by increasing expression level of target FMOD gene, wherein the gene-therapeutic DNA vector contains a coding portion of the target FMOD gene cloned into the VTvaf17 gene-therapeutic DNA vector to obtain a VTvaf17-FMOD gene-therapeutic DNA vector, with the nucleotide sequence SEQ ID No. 4. There are described methods of obtaining described vectors. What is also described is the use of said vectors for treating diseases characterized by developing tissue fibrosis, scar formation, connective tissue damage and accelerated wound repair, re-epithelialization, to increase formation of granulation tissue and inhibition of scar tissue formation, by increasing expression level of target gene SKI, or TGFB3, or TIMP2, or FMOD. There are presented the following strains: EscherichiacoliSCS110-AF/VTvaf17-SKI, strain EscherichiacoliSCS110-AF/VTvaf17-TGFB3, strain EscherichiacoliSCS110-AF/VTvaf17-TIMP2, strain EscherichiacoliSCSI 10-AF/VTvaf17-FMOD, and a method for production thereof.EFFECT: invention extends the range of products for treating diseases characterized by developing tissue fibrosis, scar formation, connective tissue damage and accelerated wound healing, re-epithelialization, increased granulation tissue formation and inhibition of scar tissue formation.14 cl, 15 dwg, 20 ex
Year: 2019
Country: RU
Doc No: 2705256